Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization - Top-Institutions - MDSpire

Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization

  • By

  • Meng Hu

  • Nan Zhang

  • Ya-Qi Wang

  • Xiao-Ming Wang

  • Yun Shi

  • Min Yao

  • Lian-Guo Hou

  • Ling-Ling Jiang

  • July 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Nanjing Drum Tower Hospital
    Nanjing Drum Tower Hospital

    Nanjing, Jiangsu

    Key Differentiators

    • Oncology

  • #3

    Chinese Academy of Sciences
    Chinese Academy of Sciences

    Shanghai, Shanghai

    Key Differentiators

    • Oncology

  • #4

    Shanghai Cancer Institute & Department of Renji Hospital
    Shanghai Cancer Institute & Department of Renji Hospital

    Shanghai, Shanghai

    Key Differentiators

    • Oncology

  • #5

    Mayo Clinic Comprehensive Cancer Center
    Mayo Clinic Comprehensive Cancer Center

    Rochester, Minnesota

    Key Differentiators

    • Oncology

Original Source(s)

Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization

  • by Meng Hu, Nan Zhang, Ya-Qi Wang, Xiao-Ming Wang, Yun Shi, Min Yao, Lian-Guo Hou, Ling-Ling Jiang

  • July 2, 2026

Related Content

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

Editorial: National Colorectal Cancer Awareness Month 2025: Current Progress and Future Prospects on Colorectal Cancer Prevention, Diagnosis and Treatment

Case Report: Melanoma of the hard palate presenting initially with gastrointestinal symptoms: the diagnostic pivotal role of 18F-FDG PET/CT